Cryoballoon ablation of paroxysmal atrial fibrillation: 5-year outcome after single procedure and predictors of success
Key result
Cryoballoon ablation for paroxysmal atrial fibrillation achieved a 5-year success rate of 53%, with normalized left atrium ≥10.25 being the sole independent predictor of recurrence (HR 2.11).
Why the study?
Does pulmonary vein isolation using cryoballoon ablation prevent recurrence of atrial arrhythmias in patients with symptomatic, drug-refractory paroxysmal atrial fibrillation over 5 years?
Population
163 patients with symptomatic, drug refractory paroxysmal atrial fibrillation (PAF)
Design
Cohort
Follow-up
5 years
Authors
Discussion
Loading...
Member takes
Implication
A single cryoballoon ablation procedure maintains sinus rhythm at 5 years in 53% of patients with drug-refractory paroxysmal AF, with enlarged left atrium predicting higher recurrence.
Study Design
Type
Cohort (n=163)
Multicenter
No
Structured PICO
Does pulmonary vein isolation using cryoballoon ablation prevent recurrence of atrial arrhythmias in patients with symptomatic, drug-refractory paroxysmal atrial fibrillation over 5 years?
P
Population
163 patients with symptomatic, drug refractory paroxysmal atrial fibrillation (PAF)
I
Intervention
Pulmonary vein isolation (PVI) with cryoballoon (CB) technique (single procedure)
O
Outcome
First electrocardiogram-documented recurrence of AF, atrial tachycardia or atrial flutter (AFLAT) at 5 yearshard clinical
A single cryoballoon ablation procedure maintains sinus rhythm at 5 years in 53% of patients with drug-refractory paroxysmal AF, with enlarged left atrium predicting higher recurrence.
Cite This Study
Neumann et al. (2013) conducted a cohort in paroxysmal atrial fibrillation (PAF) (n=163). Cryoballoon (CB) ablation was evaluated on first electrocardiogram-documented recurrence of AF, atrial tachycardia or atrial flutter (AFLAT). Cryoballoon ablation for paroxysmal atrial fibrillation achieved a 5-year success rate of 53%, with normalized left atrium ≥10.25 being the sole independent predictor of recurrence (HR 2.11).